Although the precise mechanism of BET protein-mediated renal fibrosis remains incompletely understood, studies from animal models of CKD and a clinical trial in patients with CKD have provided evidence for therapeutic potential of BET inhibitors in the treatment of renal fibrosis and associated cardiovascular events in CKD. The gene discussed is DNER; the disease is chronic kidney disease.